gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Pituitary tumor-transforming 1

The encoded protein is a homolog of yeast securin proteins, which prevent separins from promoting sister chromatid separation. It is an anaphase-promoting complex (APC) substrate that associates with a separin until activation of the APC. The gene product has transforming activity in vitro and tumorigenic activity in vivo, and the gene is highly expressed in various tumors. The gene product contains 2 PXXP motifs, which are required for its transforming and tumorigenic activities, as well as for its stimulation of basic fibroblast growth factor expression. It also contains a destruction box (D box) that is required for its degradation by the APC. The acidic C-terminal region of the encoded protein can act as a transactivation domain. The gene product is mainly a cytosolic protein, although it partially localizes in the nucleus. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: p53, PCNA, HAD, Fibroblast Growth Factor 2, CAN
Papers on PTTG
Identification of potential therapeutic targets for lung cancer by bioinformatics analysis.
Qiao et al., Liaocheng, China. In Mol Med Report, Jan 2016
A PPI module containing 34 nodes and 547 edges was obtained, including PTTG1.
Molecular Mechanisms Underlying Pituitary Pathogenesis.
Arzt et al., Buenos Aires, Argentina. In Biochem Genet, Jan 2016
Pituitary tumor transforming gene (PTTG) is an oncogene involved in early stages of pituitary tumor development, and also triggers a senescence response by activating DNA-damage signaling pathway.
Gene expression profiling of lung adenocarcinoma in Xuanwei, China.
Zhang et al., Kunming, China. In Eur J Cancer Prev, Jan 2016
The tendency of changes in the expression of 12 selected DEGs (five downregulated genes, PIK3R1, RARB, HGF, MAPK11, and SESN1, and seven upregulated genes, PAK1, E2F1, CCNE1, EGF, CDC25A, PTTG1, and UHRF1) in RTq-PCR was consistent with the expression profiling data.
Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast.
Pockaj et al., Phoenix, United States. In Oncotarget, Dec 2015
Whole genome expression analysis demonstrated consistent over-expression of genes involved in angiogenesis including VEGFA, Angiopoietin-2, VCAM1, PDGFRA, and PTTG1.
[PTTG1 enhances Hepatitis B Virus replication through P53].
Meng et al., In Wei Sheng Wu Xue Bao, Aug 2015
OBJECTIVE: To study the effect of pituitary tumor-transforming gene 1 (PTTG1) on Hepatitis B Virus (HBV) replication.
Network-assisted analysis of primary Sjögren's syndrome GWAS data in Han Chinese.
Wang et al., Beijing, China. In Sci Rep, 2014
Of these pSS candidates, 14 genes had been reported to be associated with any of pSS, RA, and SLE, including STAT4, GTF2I, HLA-DPB1, HLA-DRB1, PTTG1, HLA-DQB1, MBL2, TAP2, CFLAR, NFKBIE, HLA-DRA, APOM, HLA-DQA2 and NOTCH4.
Angiogenesis in pituitary adenomas: human studies and new mutant mouse models.
Becu-Villalobos et al., Buenos Aires, Argentina. In Int J Endocrinol, 2013
For example, VEGF, FGF-2, FGFR1, and PTTG, which give a particular vascular phenotype, are modified in human and experimental pituitary adenomas of different histotypes.
Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome.
Sivils et al., Oklahoma City, United States. In Nat Genet, 2013
We also observed suggestive associations (Pmeta < 5 × 10(-5)) with variants in 29 other regions, including TNFAIP3, PTTG1, PRDM1, DGKQ, FCGR2A, IRAK1BP1, ITSN2 and PHIP, among others.
The genetics of psoriasis and psoriatic arthritis.
Chandran, Toronto, Canada. In Clin Rev Allergy Immunol, 2013
The susceptibility genes identified include HLA-C, IL13, IL4, TNFAIP3, IL23A, IL23R, IL28RA, REL, IFIH1, ERAP, TRAF3IP2, NFKBIA, TYK2, ZNF313, NOS2, FBXL19 and NFKBIA in subjects of European ethnicity and HLA-C, IL12B, LCE3D, ERAP1, TNIP1, PTTG1, CSMD1, GJB2, SERPINB8 and ZNF816A in subjects of Chinese ethnicity.
Expression of the PTTG1 oncogene is associated with aggressive clear cell renal cell carcinoma.
Teh et al., Grand Rapids, United States. In Cancer Res, 2012
Expression of the PTTG1 oncogene is associated with aggressive clear cell renal cell carcinoma.
Pituitary tumor-transforming gene 1 enhances proliferation and suppresses early differentiation of keratinocytes.
Otsuka et al., Tsukuba, Japan. In J Invest Dermatol, 2012
PTTG1 could alter the proliferation status by modulating the expression levels of the other cell cycle regulatory proteins, and excess PTTG1 primarily affects early differentiation of keratinocytes.
PTTG-binding factor (PBF) is a novel regulator of the thyroid hormone transporter MCT8.
McCabe et al., Birmingham, United Kingdom. In Endocrinology, 2012
PBF is the first protein to interact with the critical TH transporter MCT8 and modulate its function in vivo
PTTG1 oncogene promotes tumor malignancy via epithelial to mesenchymal transition and expansion of cancer stem cell population.
Lee et al., Seoul, South Korea. In J Biol Chem, 2012
PTTG1-mediated malignant tumor properties were due, at least in part, to activation of AKT, known to be a key regulator of both EMT and stemness in cancer cells.
The pituitary tumor transforming gene in thyroid cancer.
McCabe et al., Birmingham, United Kingdom. In J Endocrinol Invest, 2012
The pituitary tumor transforming gene (PTTG) is a multifunctional proto-oncogene that is over-expressed in various tumors including thyroid carcinomas, where it is a prognostic indicator of tumor recurrence.
The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor.
Zhang et al., Ürümqi, China. In Clin Lab, 2011
The combination of Galectin-3 and PTTG is complementary as a diagnostic biomarker for patients with papillary carcinoma.
Expression and function of the novel proto-oncogene PBF in thyroid cancer: a new target for augmenting radioiodine uptake.
McCabe et al., Birmingham, United Kingdom. In J Endocrinol, 2011
Pituitary tumor-transforming gene (PTTG)-binding factor (PBF; PTTG1IP) was initially identified through its interaction with the human securin, PTTG.
Association analyses identify six new psoriasis susceptibility loci in the Chinese population.
Zhang et al., Hefei, China. In Nat Genet, 2010
We identified six new susceptibility loci associated with psoriasis in the Chinese study containing the candidate genes ERAP1, PTTG1, CSMD1, GJB2, SERPINB8 and ZNF816A (combined P < 5 × 10⁻⁸) and replicated one locus, 5q33.1 (TNIP1-ANXA6), previously reported (combined P = 3.8 × 10⁻²¹) in the European studies.
Pituitary tumor-transforming gene: physiology and implications for tumorigenesis.
Melmed et al., Los Angeles, United States. In Endocr Rev, 2007
Pituitary tumor-transforming gene-1 (PTTG1) is overexpressed in a variety of endocrine-related tumors, especially pituitary, thyroid, breast, ovarian, and uterine tumors, as well as nonendocrine-related cancers involving the central nervous, pulmonary, and gastrointestinal systems.
Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis.
Pintor-Toro et al., Sevilla, Spain. In Nat Genet, 2002
the oncogenic effect of increased expression of securin may result from modulation of p53 functions
Expression of pituitary-tumour transforming gene in colorectal tumours.
Melmed et al., Los Angeles, United States. In Lancet, 2000
Pituitary-tumour transforming gene (PTTG1) causes in-vitro and in-vivo transformation, regulates secretion of basic fibroblast growth factor, and inhibits chromatid separation.
share on facebooktweetadd +1mail to friends